Company Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Why Investors Should Care
Revenue has grown at a 41.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $655.35M (+8.3% YoY); net profit $-136.23M.
- Trailing 12 Months Year-on-year growth — revenue +12.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.29% |
| 1 Year: | 12.30% |
Stock Price Performance
| 1 Year: | -10.73% |
| 6 Months: | +8.36% |
| 3 Months: | +45.06% |
| 1 Month: | -12.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 41.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCR NovoCure Limited R2K | 15.55 | -10.16 | $1.80B | 0.00% | -26.47% | -49.96% | 41.29% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 13.05M | 17.92M | 21.67M | 30.24M | 34.88M | 38.38M | 50.11M | 53.66M | 52.12M | 61.51M | 64.76M | 69.67M | 73.31M | 86.71M | 92.06M | 99.23M | 101.83M | 115.92M | 132.66M | 143.95M | 134.69M | 133.52M | 133.61M | 133.21M | 137.55M | 140.87M | 131.00M | 128.43M | 122.18M | 126.05M | 127.32M | 138.50M | 150.36M | 155.09M | 154.99M | 158.81M | 167.20M | 174.06M |
| Gross Profit | 3.29M | 6.08M | 5.07M | 1.71M | 10.56M | 19.27M | 23.22M | 25.22M | 34.96M | 38.02M | 33.89M | 41.68M | 45.81M | 46.65M | 53.49M | 65.61M | 69.16M | 74.45M | 77.33M | 90.45M | 104.27M | 115.82M | 108.31M | 104.92M | 103.40M | 103.53M | 109.82M | 112.36M | 101.25M | 99.54M | 92.57M | 92.03M | 95.23M | 104.81M | 115.70M | 119.72M | 116.47M | 117.33M | 122.47M | 135.13M |
| Operating Income | -24.24M | -30.61M | -31.94M | -37.24M | -28.27M | -17.88M | -13.37M | -15.53M | -5.92M | -4.51M | -12.68M | -7.08M | -5.25M | -8.66M | -6.12M | 1.20M | 3.85M | 153.00K | -3.38M | 6.67M | 15.02M | 12.09M | -88.00K | -12.29M | -8.55M | -23.40M | -806.00K | -21.13M | -24.61M | -42.98M | -60.25M | -62.66M | -58.24M | -41.52M | -33.58M | -32.09M | -37.87M | -39.52M | -36.02M | -67.42M |
| Net Income | -26.02M | -32.93M | -35.44M | -40.61M | -33.63M | -22.17M | -18.05M | -21.17M | -11.50M | -10.95M | -20.72M | -15.51M | -11.69M | -15.63M | -12.15M | -1.27M | 1.93M | 4.26M | 3.95M | 1.66M | 9.28M | 4.92M | -4.13M | -14.64M | -13.12M | -26.46M | -4.65M | -24.01M | -26.58M | -37.30M | -53.06M | -57.42M | -49.48M | -38.76M | -33.38M | -30.57M | -34.32M | -40.14M | -37.27M | -71.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | - | -0.13 | -0.01 | 0.02 | 0.04 | 0.04 | 0.02 | 0.09 | 0.04 | -0.04 | -0.14 | -0.13 | -0.25 | -0.04 | -0.23 | -0.25 | -0.36 | -0.50 | -0.54 | -0.46 | -0.36 | -0.31 | -0.28 | -0.31 | -0.36 | -0.33 | -0.62 |
| R&D Expense | 10.21M | - | 11.45M | 11.32M | 10.23M | - | 9.41M | 9.37M | 9.27M | - | 11.10M | 11.36M | 13.07M | - | 17.04M | 19.45M | 18.77M | - | 25.27M | 29.92M | 32.82M | - | 45.92M | 50.31M | 48.14M | - | 42.23M | 57.08M | 51.96M | - | 59.70M | 55.43M | 53.62M | 51.60M | 54.95M | 51.88M | 53.78M | 55.83M | 54.03M | 58.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.36M | 15.49M | 33.09M | 82.89M | 177.03M | 248.07M | 351.32M | 494.37M | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M |
| Gross Profit | 3.35M | 5.45M | 12.48M | 36.61M | 121.42M | 168.02M | 262.71M | 387.87M | 420.15M | 422.97M | 381.06M | 468.04M | 488.47M |
| Operating Income | -64.46M | -80.16M | -104.00M | -115.32M | -39.33M | -33.67M | -914.00K | 30.40M | -44.33M | -89.52M | -232.87M | -170.50M | -153.80M |
| Net Income | -77.37M | -80.68M | -111.58M | -131.84M | -61.66M | -63.56M | -7.23M | 19.81M | -58.35M | -92.53M | -207.04M | -168.63M | -136.23M |
| Diluted EPS | - | - | - | - | - | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 |
| R&D Expense | 34.80M | 40.38M | 43.75M | 41.47M | 38.10M | 50.57M | 79.00M | 132.01M | 201.30M | 206.09M | 223.06M | 209.65M | 224.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 117.88M | 307.34M | 282.08M | 265.30M | 339.79M | 479.45M | 1.05B | 1.14B | 1.19B | 1.15B | 1.24B | 804.33M |
| Total Equity | 49.42M | 171.78M | 97.88M | 250.82M | 142.34M | 113.56M | 112.26M | 217.79M | 476.53M | 410.49M | 441.17M | 362.50M | 360.18M | 340.47M |
| Cash & Equivalents | 34.89M | 175.89M | 57.61M | 119.42M | 99.78M | 78.59M | 140.62M | 177.32M | 234.67M | 208.80M | 115.33M | 240.82M | 163.77M | 93.55M |
| Long Term Debt | - | - | 0 | 23.10M | 96.23M | 97.34M | 149.27M | 149.42M | 429.90M | 562.22M | 565.51M | 568.82M | 97.30M | 195.05M |
| Total Liabilities | - | - | 20.00M | 56.52M | 139.74M | 151.73M | 227.53M | 261.66M | 575.46M | 729.00M | 750.48M | 783.63M | 880.61M | 463.86M |
| Current Liabilities | - | - | 17.67M | 28.63M | 36.88M | 50.20M | 64.56M | 86.31M | 113.61M | 142.60M | 158.78M | 179.12M | 756.39M | 223.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -107.59M | -33.13M | -1.86M | 26.62M | 99.15M | 82.76M | 30.79M | -73.34M | -26.37M | -49.03M |
| Investing Cash Flow | - | - | - | 13.00M | 8.63M | -5.49M | -51.67M | -472.85M | -144.83M | -139.96M | 184.15M | -140.24M | 437.28M |
| Financing Cash Flow | - | - | - | 75.12M | 5.17M | 69.37M | 61.68M | 440.21M | 25.70M | 15.49M | 15.79M | 90.31M | -451.34M |
| Capital Expenditure | -2.20M | -849.00K | -4.67M | -5.67M | -7.37M | -6.71M | -10.48M | -14.97M | -24.17M | -21.36M | -27.09M | -42.85M | -26.65M |
| Free Cash Flow | - | - | - | -113.27M | -40.50M | -8.58M | 16.14M | 84.18M | 58.59M | 9.43M | -100.43M | -69.22M | -75.68M |
| Share Buybacks | - | - | 5.00K | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 32.3% | 35.2% | 37.7% | 44.2% | 68.6% | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating Margin % | -622.3% | -517.5% | -314.3% | -139.1% | -22.2% | -13.6% | -0.3% | 6.1% | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Net Margin % | -746.9% | -520.9% | -337.2% | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| ROE % | -45.0% | -82.4% | -44.5% | -92.6% | -54.3% | -56.6% | -3.3% | 4.2% | -14.2% | -21.0% | -57.1% | -46.8% | -40.0% |
| ROCE % | - | -80.0% | -37.3% | -47.0% | -18.3% | -12.2% | -0.2% | 3.2% | -4.4% | -8.7% | -24.1% | -35.2% | -26.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.74% | 17.07M | $301.10M |
| 2 | Blackrock Inc. | 11.39% | 13.19M | $232.74M |
| 3 | Soleus Capital Management, L.P. | 9.06% | 10.49M | $185.09M |
| 4 | Vanguard Portfolio Management LLC | 5.40% | 6.25M | $110.28M |
| 5 | Vanguard Capital Management LLC | 4.04% | 4.68M | $82.59M |
| 6 | Morgan Stanley | 3.92% | 4.54M | $80.11M |
| 7 | Wells Fargo & Company | 2.55% | 2.95M | $52.06M |
| 8 | State Street Corporation | 2.21% | 2.56M | $45.19M |
| 9 | Geode Capital Management, LLC | 2.17% | 2.51M | $44.31M |
| 10 | Quantinno Capital Management, LP | 2.15% | 2.49M | $43.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVCR
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE40Wklqd2VRdkhGb0lNbTVCYkV3SzNOUEpYNU5vdW9jSkdfS25aQVZXcHE0WHlSNGhuRTlCd2ZkUUlES3VfNTZGX1M1a2VsaGlq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQZVROODdxZjFGT2NtcTl4XzF3VndicEZXZXFLeGdnUkVrdHlZYi1vS2hqMjdQRHNRaEZXRHdBd0VmYkpVOTg1alFwVjFidHduZzZuRlQzaHNXM1VSbWppZWdxMmlOLWpXLUxwVzlEdjZQOHp0RVU4WDdnOXU4WVdUQjZ6V0RkeS1aQmFFOX…
Why NVCR Stock Is Surging Nearly 30% In Overnight Trading - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQS2xlN1dqWHd3dVpxTG1TZmJJZEN2RE1Qb0kyd0JaQXlEUmJSazBzZk80NE9CY2FTbVd0QVNqME0xTFNNRV9mYUpEUUh2bEQ2bjE4dV9od3JDNmtHM19Oa3Q2M01Dd3ZpQ1FMVmdCc2VDZU84M1VmcFBUcHF6WllYckxsbkdGel82WGozbX…
NVCR Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9qd3RMYU9yMlN5WV85Wm52a0JKbTJnaFZKQ3dCNFZ4UVdIT1Q5ck5KUUhKUVNOa1pNTDZFcEJJbktBWjByMlJGSmpndnhWaXdxdkhsa2hfY3hmeEZiWlY0TE1jWVZpNlJ2ZDV3ekx3U282NDVySENQQlVR?oc=5" target="_blank">NVC…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNRUZzYUdSTnlZZ0Vib3B1YUotVFFvcl9ld1o4TG5YVVVXa1lhYXNiZy1Rdk5ra3NDeDA4cUt4MTVVam93MlpFUUp6MFBWTUhsUXdIemplT2IzbE1DNVh1eV9RYkN4dTdFdWVCM0d4UkQxVUlnWEJFOGNGczlOOU9xV1ZCZXd3WE9zeGpnZl…
JPMorgan Initiates Coverage on Novocure (NVCR) with Neutral Outl - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOb1AtcnVxeHNUU0RLUnBIRDRWTk54YTNkV1kxaHdGelRYZTNKVlJyRWdwR3MtT0IwVkNGYURnZXAxU3c5MmltTVZRMDNldjdXU0trQTRlUElTUWdicHNGdnJ0b2pIUURteWlHOHVVV1g3d3RHTVBFTWxMV0VSMUhzMS1xVGRRRVRkRTZ6Z2…
NVCR — Frequently Asked Questions
What is the current share price of NovoCure Limited (NVCR)?
As of 2026-07-14 21:23 PDT, NovoCure Limited (NVCR) trades at $15.55 on NasdaqGS. Its 52-week range is $10.03 to $18.31.
What is the market capitalisation of NVCR?
NovoCure Limited (NVCR) has a market capitalisation of $1.80B on NasdaqGS.
What is the P/E ratio of NVCR?
NVCR trades at a trailing price-to-earnings (P/E) ratio of -10.16. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.23.
What is the return on equity (ROE) of NVCR?
NVCR has a return on equity (ROE) of -49.96%. Its return on capital employed (ROCE) is -26.47%.
Is NVCR a good stock to buy?
This page provides a data-driven analysis of NovoCure Limited (NVCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.